Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 1141
interventional 1061
Observational 70
Registry 10

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 531
Biological 105
Biological|Drug 67
Drug|Other 67
Biological|Drug|Other 32
Drug|Procedure 30
Biological|Drug|Procedure|Radiation 25
Biological|Other 18
Drug|Procedure|Radiation 16
Drug|Other|Procedure|Radiation 12
Drug|placebo 11
Drug|Radiation 11
Procedure 11
Biological|Drug|Other|Procedure|Radiation 10
Biological|Drug|Other|Procedure 8
Biological|Drug|Procedure 8
Other 8
Biological|Drug|Radiation 7
Drug|Other|Procedure 7
Biological|Other|Procedure 6
Drug|Genetic 6
Biological|Radiation 5
Device 5
Drug|Genetic|Other 4
Radiation 4
Behavioral 3
Device|Drug|Procedure 3
Dietary Supplement|Other 3
Biological|Device|Drug 2
Biological|Drug|Genetic 2
Biological|Procedure 2
Biological|Procedure|Radiation 2
Combination Product|Drug 2
Diagnostic Test 2
Genetic 2
Other|Procedure 2
Behavioral|Drug 1
Biological|Device|Drug|Procedure|Radiation 1
Biological|Dietary Supplement|placebo 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Genetic|Other|Procedure 1
Biological|Drug|Other|Radiation 1
Biological|Genetic|Other 1
Combination Product 1
Device|Drug 1
Device|Procedure 1
Diagnostic Test|Drug|Genetic|Procedure|Radiation 1
Diagnostic Test|Drug|Procedure 1
Dietary Supplement 1
Dietary Supplement|Drug 1
Dietary Supplement|Other|placebo 1
Drug|Genetic|Other|Procedure|Radiation 1
Drug|Genetic|Procedure 1
Drug|Genetic|Procedure|Radiation 1
Drug|Other|placebo|Procedure 1
Drug|Other|Radiation 1
Drug|placebo|Procedure 1
Genetic|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 588
NA 44
China 43
United States|Canada 34
Germany 25
Canada 21
Japan 18
France 17
United States|Puerto Rico 14
Italy 13
Korea, Republic of 10
Spain 9
United Kingdom 8
Taiwan 7
United States|Australia|Canada 5
United States|Germany|Italy 5
United States|United Kingdom 5
United States|Australia 4
United States|France 4
United States|Italy 4
Israel 3
Russian Federation 3
United States|Canada|France|Netherlands 3
United States|Germany 3
Belgium|France 2
France|United Kingdom 2
Italy|Switzerland 2
Japan|Korea, Republic of 2
Norway 2
Switzerland 2
United States|Canada|Puerto Rico 2
United States|Denmark|Germany 2
United States|France|Germany|Spain 2
United States|France|Spain|United Kingdom 2
United States|France|United Kingdom 2
United States|Korea, Republic of 2
United States|Switzerland 2
Albania|Argentina|Australia|Bosnia and Herzegovina|Brazil|Bulgaria|Colombia|Croatia|Ecuador|Egypt|Finland|Germany|Greece|Israel|Italy|Mexico|Romania|Russian Federation|Slovakia|Slovenia|Spain|Sweden|Switzerland|Turkey 1
Albania|Argentina|Austria|Brazil|Bulgaria|Colombia|Ecuador|Egypt|France|Germany|Greece|Hungary|Italy|Lithuania|Norway|Romania|Russian Federation|Slovakia|Slovenia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Algeria|Morocco|Tunisia 1
Argentina 1
Australia|Belgium|Bosnia and Herzegovina|Brazil|Bulgaria|Canada|Colombia|Croatia|Denmark|Finland|France|Georgia|Germany|Greece|Italy|Macedonia, The Former Yugoslav Republic of|Malaysia|Mexico|New Zealand|Peru|Romania|Russian Federation|Serbia|Singapore|Slovakia|South Africa|Spain|Thailand|Turkey|United Kingdom 1
Australia|Belgium|Denmark|Italy|Spain 1
Australia|Canada|France|Italy|Sweden|Switzerland 1
Australia|France|Germany|Hungary|Korea, Republic of|Poland|Singapore|United Kingdom 1
Australia|France|Germany|Italy|Spain|United Kingdom 1
Australia|France|Spain|United Kingdom 1
Austria 1
Austria|Belgium|China|Czechia|Denmark|Finland|France|Germany|Hungary|Ireland|Israel|Italy|Netherlands|Norway|Poland|Portugal|Russian Federation|Slovakia|Spain|Sweden|Switzerland 1
Austria|Belgium|Finland|France|Germany|Italy|Japan|Netherlands|Spain|Switzerland|United Kingdom 1
Austria|Belgium|France|Germany|Israel|Netherlands|Poland|Portugal 1
Belgium 1
Belgium|Canada|China|France|Hungary|Italy|Netherlands|Poland|Spain|United Kingdom 1
Belgium|Canada|Denmark|France|Germany|Italy|Netherlands|Norway|Portugal|Spain|Sweden|Switzerland|United Kingdom 1
Belgium|Croatia|Czechia|Hungary|Poland|Portugal|Romania|Spain|Turkey|United Kingdom 1
Belgium|Croatia|Egypt|France|Netherlands 1
Belgium|Denmark|Italy|Spain|United Kingdom 1
Belgium|Egypt|France|Netherlands|Portugal|Switzerland|United Kingdom 1
Belgium|France|United Kingdom 1
Belgium|Lithuania|Spain 1
Belgium|Netherlands 1
Brazil 1
Brazil|Bulgaria|China|Greece|Italy|Korea, Republic of|Poland|Portugal|Russian Federation|South Africa|Taiwan|Turkey 1
Brazil|United States|Argentina|Austria|Belgium|Canada|Croatia|Denmark|Greece|Italy|Netherlands|Poland|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Canada|United States 1
Canada|United States|Australia|New Zealand|Switzerland 1
Chile|Italy|Spain|Switzerland 1
Colombia|India|Russian Federation|South Africa|Ukraine 1
Colombia|Mexico 1
Denmark|Finland|Netherlands|Norway|Sweden 1
Finland 1
France|Germany 1
France|Germany|Korea, Republic of 1
France|Italy|Japan|Spain 1
France|Italy|Netherlands 1
France|Italy|Peru|Puerto Rico|Spain|Switzerland 1
France|Italy|Spain|United Kingdom 1
France|Italy|Switzerland 1
France|Spain 1
Germany|Italy|Spain 1
Germany|Netherlands|United Kingdom 1
Germany|Switzerland 1
Germany|United States|Belgium|France|Spain|Switzerland|United Kingdom 1
Hungary|Argentina|Australia|Austria|Brazil|Canada|Chile|Colombia|Croatia|Denmark|Dominican Republic|Egypt|El Salvador|Germany|Guatemala|Hong Kong|Indonesia|Italy|Korea, Republic of|Malaysia|Netherlands|New Zealand|Panama|Peru|Philippines|Portugal|Romania|Sweden|Taiwan|Thailand|Turkey|Vietnam 1
India 1
Italy|Japan|United States|Australia|France|Greece 1
Italy|Saudi Arabia|United Kingdom 1
Italy|United Kingdom 1
Japan|United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Chile|China|Colombia|France|Germany|Greece|Hong Kong|Hungary|Ireland|Italy|Korea, Republic of|Lithuania|Malaysia|Mexico|New Zealand|Philippines|Poland|Portugal|Romania|Russian Federation|Singapore|Slovakia|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|Vietnam 1
Japan|United States|Argentina|Australia|Belgium|Brazil|China|France|Germany|Israel|Korea, Republic of|Poland|Puerto Rico|Russian Federation|Spain|Sweden|Turkey|Ukraine|United Kingdom 1
Kenya|Zimbabwe 1
Mexico 1
Netherlands 1
Netherlands|Australia|Belgium|Canada|Denmark|Egypt|France|Hungary|Italy|New Zealand|Norway|Poland|Portugal|Slovakia|Slovenia|South Africa|Sweden|United Kingdom 1
Puerto Rico 1
Saudi Arabia 1
Serbia 1
Singapore 1
Spain|France|Germany|Italy|Netherlands|Sweden|United Kingdom 1
Spain|United States|Australia|Bulgaria|Canada|Colombia|Czechia|France|Georgia|Germany|Greece|India|Israel|Italy|Japan|Korea, Republic of|Mexico|Poland|Romania|Ukraine 1
Spain|United States|Belgium|Germany|Hungary|Italy|Poland 1
Sweden|United Kingdom 1
Switzerland|Austria|Germany|Greece|Italy 1
Turkey 1
United States|Argentina|Australia|Belgium|Brazil|Canada|China|Cyprus|Czech Republic|Finland|France|Germany|Greece|Hungary|India|Israel|Italy|Korea, Republic of|Mexico|New Zealand|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Slovakia|South Africa|Spain|Sweden|Thailand|Ukraine|United Kingdom 1
United States|Argentina|Bulgaria|Costa Rica|Ecuador|Estonia|France|Germany|Hungary|India|Italy|Mexico|Panama|Peru|Poland|Romania|Russian Federation|Ukraine|United Kingdom|Uruguay 1
United States|Australia|Austria|Belgium|Bulgaria|Canada|Finland|France|Germany|Greece|Hong Kong|Hungary|Ireland|Israel|Italy|Korea, Republic of|New Zealand|Poland|Portugal|Russian Federation|Singapore|Spain|Sweden|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Croatia|Czechia|Denmark|Finland|France|Hungary|Ireland|Israel|Italy|Korea, Republic of|Netherlands|Norway|Poland|Singapore|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|China|France|New Zealand|Poland|Spain|Taiwan 1
United States|Australia|Austria|Belgium|Czechia|France|Germany|Italy|Japan|Netherlands|Singapore|Spain|Switzerland|Taiwan 1
United States|Australia|Austria|Canada|Czechia|France|Hungary|Italy|Netherlands|Spain 1
United States|Australia|Austria|Canada|Denmark|Finland|France|Italy|Japan|Netherlands|Norway|Spain 1
United States|Australia|Austria|France|Germany|Hong Kong|Italy|Japan|Netherlands|Norway|Singapore|Spain|Switzerland 1
United States|Australia|Belarus|Bulgaria|Canada|China|Czechia|France|Germany|Italy|Korea, Republic of|New Zealand|Poland|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Brazil|Bulgaria|Canada|Chile|China|Czechia|Denmark|Finland|France|Germany|Greece|Hong Kong|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Mexico|Poland|Portugal|Romania|Russian Federation|Singapore|Slovakia|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Australia|Belgium|Canada|China|Czechia|Finland|France|Germany|Hungary|Israel|Italy|Japan|Russian Federation|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|Denmark|Finland|France|Italy|New Zealand|Poland|Spain|Taiwan 1
United States|Australia|Belgium|Canada|Czechia|France|Greece|Israel|Italy|New Zealand|Poland|Russian Federation|Spain|Sweden|Turkey 1
United States|Australia|Belgium|Canada|France|Germany|Italy|United Kingdom 1
United States|Australia|Belgium|Canada|Italy|Puerto Rico|Spain|United Kingdom 1
United States|Australia|Belgium|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Poland|Spain|Switzerland|United Kingdom 1
United States|Australia|Brazil|Canada|Mexico|New Zealand|Peru 1
United States|Australia|Brazil|India|Mexico|Peru 1
United States|Australia|Canada|Denmark|France|Germany|Italy|Spain|United Kingdom 1
United States|Australia|Canada|France|Germany|Korea, Republic of|Spain|United Kingdom 1
United States|Australia|Canada|France|Italy|Korea, Republic of|Poland|Singapore|Spain|Taiwan|United Kingdom 1
United States|Australia|Canada|Germany|Israel|Italy 1
United States|Australia|Canada|Ireland|New Zealand|Puerto Rico|Switzerland 1
United States|Australia|Canada|Netherlands|New Zealand|Puerto Rico|Switzerland 1
United States|Australia|Canada|Netherlands|Puerto Rico|Switzerland 1
United States|Australia|Canada|New Zealand 1
United States|Australia|Canada|Puerto Rico 1
United States|Australia|Canada|Puerto Rico|Switzerland 1
United States|Australia|Czechia|France|Germany|Italy|Korea, Republic of|Poland|Romania|Russian Federation|Serbia 1
United States|Australia|France|Germany|Israel|Korea, Republic of|Spain 1
United States|Australia|France|Germany|Italy 1
United States|Australia|France|Greece|Hong Kong|Poland|Russian Federation|Singapore 1
United States|Australia|France|Italy|Japan 1
United States|Australia|France|Poland 1
United States|Australia|Germany 1
United States|Australia|Israel|Italy|Korea, Republic of|Poland|Slovakia|Spain|United Kingdom 1
United States|Austria|Belgium|Bulgaria|Czechia|Denmark|France|Germany|Hungary|Italy|Poland|Romania|Russian Federation|Slovakia|Spain|Ukraine|United Kingdom 1
United States|Austria|Belgium|Canada|Czechia|France|Germany|Italy|Netherlands|Russian Federation|Spain|Sweden|Switzerland|United Kingdom 1
United States|Austria|Czech Republic|France|Germany|Lithuania|Romania|Russian Federation|Sweden|Turkey|United Kingdom 1
United States|Austria|Korea, Republic of|Spain 1
United States|Belarus|Belgium|Bulgaria|Canada|Czechia|France|Georgia|Hungary|Italy|Spain|United Kingdom 1
United States|Belgium|Brazil|Bulgaria|Canada|Czechia|France|Germany|Hungary|Italy|Korea, Republic of|Netherlands|Poland|Romania|Russian Federation|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Belgium|Brazil|China|Czechia|France|Germany|Israel|Italy|Japan|Poland|Portugal|Puerto Rico|Russian Federation|Spain|Turkey|United Kingdom 1
United States|Belgium|Bulgaria|Czechia|Hungary|Italy|Poland|Switzerland|Ukraine 1
United States|Belgium|Canada|France|Hong Kong|Japan|Korea, Republic of|Singapore|United Kingdom 1
United States|Belgium|Canada|France|United Kingdom 1
United States|Belgium|France|Germany|Italy|Japan|Netherlands|Spain|Sweden|Switzerland|United Kingdom 1
United States|Belgium|France|Italy|Netherlands|Spain 1
United States|Belgium|France|Italy|Spain 1
United States|Belgium|Germany|Hong Kong|Hungary|Japan|Korea, Republic of|Netherlands|Singapore 1
United States|Belgium|Israel 1
United States|Canada|China|France|Germany|Hong Kong|Italy|Taiwan 1
United States|Canada|France|Germany|Israel|Netherlands 1
United States|Canada|France|Germany|Italy|Netherlands 1
United States|Canada|France|Germany|Italy|Spain|United Kingdom 1
United States|Canada|France|Germany|Netherlands|United Kingdom 1
United States|Canada|France|Italy|Spain 1
United States|Canada|France|Italy|Spain|United Kingdom 1
United States|Canada|France|Spain 1
United States|Canada|Germany 1
United States|Canada|Korea, Republic of|Taiwan 1
United States|Czechia|Italy|Korea, Republic of|Poland|Russian Federation 1
United States|Denmark 1
United States|Egypt|India 1
United States|France|Germany 1
United States|France|Germany|Italy|Mexico|Netherlands|Spain|United Kingdom 1
United States|France|Germany|Italy|Poland|United Kingdom 1
United States|Germany|Israel|Netherlands 1
United States|Germany|Puerto Rico 1
United States|India|Israel 1
United States|Italy|United Kingdom 1
United States|Japan 1
United States|Kenya|Uganda 1
United States|Netherlands 1
United States|Poland 1
United States|Poland|Spain|Sweden 1
United States|Russian Federation 1

Sites per Study

Site_count Study_Count
1 479
2 80
3 51
4 37
5 41
6 21
7 19
8 17
9 14
10 16
11 30
12 13
13 8
14 13
15 8
16 9
17 11
18 6
19 5
20 9
21 9
22 13
23 8
24 1
25 8
26 3
27 7
28 4
30 2
31 5
32 4
33 1
34 5
35 2
36 2
38 4
39 2
40 2
41 5
42 3
43 2
45 2
46 3
47 1
48 3
51 1
52 1
53 2
56 1
57 1
60 1
62 1
65 1
67 1
68 1
71 2
73 1
76 1
77 1
79 1
81 1
87 1
91 2
92 2
94 2
95 1
98 1
99 1
101 1
104 1
106 1
108 1
111 2
112 1
113 2
114 2
116 1
117 1
118 1
119 1
121 1
128 1
129 1
131 1
134 1
143 1
150 1
152 1
161 2
165 1
167 1
171 1
176 1
178 1
180 1
183 1
190 1
192 1
200 1
206 1
212 1
215 1
222 1
235 1
244 1
246 1
259 1
261 1
483 1

Phase

Phase Study_Count
Phase 2 435
Phase 1 305
Phase 1/Phase 2 151
Phase 3 85
N/A 49
Phase 4 19
Early Phase 1 12
Phase 2/Phase 3 5

Number of Arms

Number_of_Arms Count_of_Studies
1 614
2 185
3 45
4 34
5 10
6 10
7 5
8 7
9 2
10 2
12 1
13 2
15 1
17 1
NA 142

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 6.00000 2.0000 2.00000 1.00000 3.00000 80.00 14.0000 12.0000
1st Qu. 10.75000 19.2500 19.00000 32.00000 31.00000 146.75 133.5000 52.5000
Median 18.00000 41.0000 36.00000 54.00000 48.00000 278.50 318.0000 101.0000
Mean 45.58333 105.2708 57.39203 74.78523 74.13659 384.25 502.4458 191.7368
3rd Qu. 30.75000 113.5000 62.00000 92.00000 72.00000 516.00 547.0000 294.0000
Max. 312.00000 713.0000 746.00000 422.00000 3279.00000 900.00 9350.0000 650.0000

Trial Group Type

group_type Group_Count
Experimental 1375
NA 142
Active Comparator 109
Other 50
Placebo Comparator 15
No Intervention 14
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 728
Parallel Assignment 219
NA 61
Sequential Assignment 41
Crossover Assignment 7
Factorial Assignment 5

Primary Purpose

primary_purpose Study_Count
Treatment 998
Supportive Care 21
Diagnostic 13
Prevention 12
Other 7
Basic Science 5
Screening 2
NA 2
Educational/Counseling/Training 1

Observational Studies

Studies by Country

Country Study_Count
United States 29
NA 7
China 5
Italy 3
Japan 3
Korea, Republic of 3
Canada 2
France 2
United Kingdom 2
Argentina|Brazil|Chile|Colombia|Guatemala|Mexico|Panama 1
Austria|Belgium|Bulgaria|Czechia|France|Germany|Greece|Poland|Romania 1
China|Hong Kong|Taiwan 1
Israel 1
Macedonia, The Former Yugoslav Republic of 1
Netherlands 1
Russian Federation 1
Serbia 1
Spain 1
Sweden 1
Tanzania|Uganda 1
United States|Australia|Canada|Puerto Rico 1
United States|Australia|Canada|Puerto Rico|Switzerland 1
United States|Canada 1

Sites per Study

Site_count Study_Count
1 47
2 1
3 2
4 2
5 1
6 1
7 1
9 1
12 2
23 1
25 1
28 1
31 1
35 1
42 1
66 1
69 1
75 1
111 1
130 1
183 1

Enrollment Metrics

Measure Observational
Min 8.000
1st Qu 89.250
Median 172.000
Mean 1022.457
3rd Qu 773.250
Max 13433.000

Observation Model

observational_model Study_Count
Cohort 31
Case-Only 15
NA 9
Case-Control 5
Other 5
Family-Based 3
Case Control 2

Time Perspective

time_perspective Study_Count
Prospective 42
Retrospective 15
NA 7
Cross-Sectional 4
Other 2

Registries

Studies by Country

Country Study_Count
China 3
Korea, Republic of 2
United States 2
Belgium|France 1
Czechia 1
NA 1

Sites per Study

Site_count Study_Count
1 8
11 1
31 1

Enrollment Metrics

Measure Registries
Min 150.00
1st Qu 225.00
Median 400.00
Mean 3599.50
3rd Qu 2996.25
Max 20000.00

Registry Model

observational_model Study_Count
Cohort 9
Case-Only 1

Time Perspective

time_perspective Study_Count
Prospective 8
Other 2

Follow-up

target_duration Study_Count
5 Years 4
10 Years 2
3 Years 2
13 Years 1
2 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04435743 Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin’s Lymphomas https://ClinicalTrials.gov/show/NCT04435743 Recruiting Ruijin Hospital 2022-12-31
NCT04434833 A Single-cell Transcriptome Study in Patients With Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT04434833 Recruiting Ruijin Hospital 2022-06-30
NCT03289182 An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin’s Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) https://ClinicalTrials.gov/show/NCT03289182 Active, not recruiting Hoffmann-La Roche 2020-10-26
NCT03260101 Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study https://ClinicalTrials.gov/show/NCT03260101 Recruiting Cellect Biotechnology 2021-12-31
NCT03065790 Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide https://ClinicalTrials.gov/show/NCT03065790 Active, not recruiting Abramson Cancer Center of the University of Pennsylvania 2021-02-06
NCT03042247 Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03042247 Recruiting Federico II University 2020-06-10
NCT03000192 HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life https://ClinicalTrials.gov/show/NCT03000192 Active, not recruiting University Hospital Southampton NHS Foundation Trust 2020-12-31
NCT02992223 Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT https://ClinicalTrials.gov/show/NCT02992223 Completed Azienda Ospedaliera Città della Salute e della Scienza di Torino 2015-07-31
NCT02788084 Development of a Tissue-Based & Cell Free DNA Next-Generation Sequencing Workflow https://ClinicalTrials.gov/show/NCT02788084 Active, not recruiting Alberta Health Services, Calgary 2019-06-30
NCT02682667 Biospecimen Procurement for Experimental Transplantation and Immunology Branch Immunotherapy Protocols https://ClinicalTrials.gov/show/NCT02682667 Recruiting National Institutes of Health Clinical Center (CC) 2025-12-01
NCT02633111 DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT02633111 Recruiting Memorial Sloan Kettering Cancer Center 2021-10-31
NCT01676805 Tissue Collection for Studies of Lymph Cancer https://ClinicalTrials.gov/show/NCT01676805 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00923442 Biology Studies of Hematologic Cancers https://ClinicalTrials.gov/show/NCT00923442 Enrolling by invitation National Institutes of Health Clinical Center (CC) NA
NCT00131014 Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies https://ClinicalTrials.gov/show/NCT00131014 Recruiting Dana-Farber Cancer Institute 2023-01-31
NCT00039676 Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer https://ClinicalTrials.gov/show/NCT00039676 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02559583 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin’s Lymphoma (NHL) in Latin America https://ClinicalTrials.gov/show/NCT02559583 Completed Janssen-Cilag Ltd. 2016-06-30
NCT02486952 MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02486952 Completed Hoffmann-La Roche 2011-01-31
NCT02434484 Symbenda Post-Marketing Surveillance (PMS) https://ClinicalTrials.gov/show/NCT02434484 Active, not recruiting Eisai Inc. 2020-04-30
NCT02199288 Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin’s Lymphoma: Real-Life Setting https://ClinicalTrials.gov/show/NCT02199288 Completed Hoffmann-La Roche 2016-07-31
NCT02178475 Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin’s Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy https://ClinicalTrials.gov/show/NCT02178475 Completed Amgen 2016-10-28
NCT02139592 Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) “Relapsed or Refractory CD30+ Hodgkin’s Lymphoma or Anaplastic Large Cell Lymphoma” https://ClinicalTrials.gov/show/NCT02139592 Completed Takeda 2017-06-30
NCT02072967 Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT02072967 Completed Astellas Pharma Inc 2015-10-31
NCT01988272 Imaging Based Dosimetry for Individualized Internal Emitter Therapy https://ClinicalTrials.gov/show/NCT01988272 Completed University of Michigan 2015-03-31
NCT01763398 Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study https://ClinicalTrials.gov/show/NCT01763398 Completed Yonsei University 2015-08-31
NCT01684865 An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01684865 Completed Hoffmann-La Roche 2017-11-27
NCT01623856 Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients https://ClinicalTrials.gov/show/NCT01623856 Completed Children’s Oncology Group 2012-06-30
NCT01584141 Study of Lymphoma in Asia https://ClinicalTrials.gov/show/NCT01584141 Completed National Institutes of Health Clinical Center (CC) NA
NCT01565447 Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Gait Parameters Study https://ClinicalTrials.gov/show/NCT01565447 Active, not recruiting Oregon Health and Science University 2020-12-31
NCT01479387 Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan https://ClinicalTrials.gov/show/NCT01479387 Completed Bayer NA
NCT04320992 A Multicenter Prospective Study of “High Risk” Molecular Typing in Patients With Adult T Lymphoblastic Lymphoma https://ClinicalTrials.gov/show/NCT04320992 Recruiting Sun Yat-sen University 2023-03-31
NCT04028804 FLT PET: A Pilot Study in Lymphoma Patients https://ClinicalTrials.gov/show/NCT04028804 Completed The Hospital for Sick Children 2014-12-31
NCT03930043 A Metagenome-wide Association Study of Gut Microbiota in Gastrointestinal Non-Hodgkin’s Lymphoma Patients https://ClinicalTrials.gov/show/NCT03930043 Recruiting Ruijin Hospital 2020-09-30
NCT03706625 Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment https://ClinicalTrials.gov/show/NCT03706625 Recruiting Assistance Publique - Hôpitaux de Paris 2021-10-31
NCT03571997 Study of Prognostic Factors in Adult Lymphoblastic Lymphoma https://ClinicalTrials.gov/show/NCT03571997 Recruiting PETHEMA Foundation 2020-09-01
NCT03480087 Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma https://ClinicalTrials.gov/show/NCT03480087 Recruiting Azienda Ospedaliera Città della Salute e della Scienza di Torino 2020-07-31
NCT03469921 Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016 https://ClinicalTrials.gov/show/NCT03469921 Completed Institut Paoli-Calmettes 2016-12-31
NCT01264822 Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori https://ClinicalTrials.gov/show/NCT01264822 Completed Eisai Inc. 2016-02-29
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01196520 Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM) https://ClinicalTrials.gov/show/NCT01196520 Completed National Institutes of Health Clinical Center (CC) 2015-12-31
NCT01135849 B-Receptor Signaling in Cardiomyopathy https://ClinicalTrials.gov/show/NCT01135849 Completed Stanford University 2010-10-31
NCT01000753 Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01000753 Active, not recruiting Children’s Oncology Group 2007-06-01
NCT00949741 Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin’s Lymphoma Patients https://ClinicalTrials.gov/show/NCT00949741 Completed Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie 2011-10-31
NCT00902434 Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era https://ClinicalTrials.gov/show/NCT00902434 Completed Oncology Specialists, S.C. 2011-02-28
NCT00903890 Cardiac Effects in Long-Term Survivors of Hodgkin’s and Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00903890 Active, not recruiting University of Rochester 2018-11-30
NCT00903812 IMPACT Non Hodgkins Lymphoma (NHL) Study https://ClinicalTrials.gov/show/NCT00903812 Completed Amgen 2008-12-31
NCT00897325 Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00897325 Completed Children’s Oncology Group 2019-12-31
NCT00898755 Collecting and Storing Tissue From Young Patients With Cancer https://ClinicalTrials.gov/show/NCT00898755 Completed Children’s Oncology Group 2008-07-17
NCT04283955 A Retrospective Cohort Study: The Influence of MTHFR C677T and A1298C on the High-dose Methotrexate-Related Toxicities in Pediatric Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT04283955 Completed Sun Yat-sen University 2019-03-01
NCT01087333 Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment https://ClinicalTrials.gov/show/NCT01087333 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00741325 Long-Term Follow-up Study for Non-Hodgkin’s Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610). https://ClinicalTrials.gov/show/NCT00741325 Completed Sanofi 2011-11-30
NCT00713882 Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors https://ClinicalTrials.gov/show/NCT00713882 Completed Weill Medical College of Cornell University 2008-11-30
NCT00712556 PET Study in Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00712556 Completed Vanderbilt-Ingram Cancer Center 2009-03-31
NCT00685997 Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas https://ClinicalTrials.gov/show/NCT00685997 Completed UMC Utrecht 2012-01-31
NCT00626496 Family Study of Lymphoproliferative Disorders https://ClinicalTrials.gov/show/NCT00626496 Recruiting Mayo Clinic 2025-12-31
NCT00587912 AIDS and Cancer Specimen Bank (ACSB) https://ClinicalTrials.gov/show/NCT00587912 Completed Memorial Sloan Kettering Cancer Center 2011-04-30
NCT00579163 Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers https://ClinicalTrials.gov/show/NCT00579163 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-12-31
NCT00510315 Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00510315 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-01-31
NCT00398177 Clinical and Pathologic Studies in Non-Hodgkin’s Lymphoma and Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00398177 Recruiting Stanford University 2099-01-31
NCT00341952 Interdisciplinary Case-Control Study of Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00341952 Completed National Institutes of Health Clinical Center (CC) NA
NCT00301288 A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL). https://ClinicalTrials.gov/show/NCT00301288 Completed Royal Marsden NHS Foundation Trust NA
NCT00240591 Patients With Low-Grade Non-Hodgkin’s Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab https://ClinicalTrials.gov/show/NCT00240591 Completed GlaxoSmithKline 2010-06-30
NCT00240578 Patients With Low-Grade Non-Hodgkin’s Lymphoma Previously Treated With Iodine I 131 Tositumomab https://ClinicalTrials.gov/show/NCT00240578 Completed GlaxoSmithKline 2013-06-30
NCT00098566 Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00098566 Completed Fred Hutchinson Cancer Research Center 2011-06-30
NCT00097565 An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00097565 Completed Genentech, Inc. 2014-03-31
NCT00003863 Diagnostic Study of Patients With Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00003863 Completed Alliance for Clinical Trials in Oncology 2005-05-31
NCT00001301 Chronic and Late Effects of Non-Hodgkin’s Lymphoma and Its Treatment in Long Term Survivors https://ClinicalTrials.gov/show/NCT00001301 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001571 A Pilot Study of Non-Hodgkin’s Lymphoma: Chemotherapy and Blood Levels of Organochlorines https://ClinicalTrials.gov/show/NCT00001571 Completed National Institutes of Health Clinical Center (CC) NA
NCT00026910 Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00026910 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001120 A Study of Patients With AIDS Syndrome https://ClinicalTrials.gov/show/NCT00001120 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00339963 Genome Expression in Lymphoma, Leukemia and Multiple Myeloma https://ClinicalTrials.gov/show/NCT00339963 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT04342117 Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL https://ClinicalTrials.gov/show/NCT04342117 Recruiting Verastem, Inc. 2023-04-30
NCT03199066 Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL) https://ClinicalTrials.gov/show/NCT03199066 Recruiting Czech Lymphoma Study Group 2020-12-31
NCT03117036 Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III https://ClinicalTrials.gov/show/NCT03117036 Recruiting Samsung Medical Center 2022-02-28
NCT02298816 B-Cell Hematologic Malignancy Vaccination Registry https://ClinicalTrials.gov/show/NCT02298816 Enrolling by invitation Aurora Health Care 2024-12-31
NCT04220970 Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry https://ClinicalTrials.gov/show/NCT04220970 Recruiting The Lymphoma Academic Research Organisation 2032-06-07
NCT03958916 Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL https://ClinicalTrials.gov/show/NCT03958916 Recruiting Sun Yat-sen University 2022-05-05
NCT03766516 Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HL https://ClinicalTrials.gov/show/NCT03766516 Recruiting Samsung Medical Center 2020-06-30
NCT00889798 Tumor Registry of Lymphatic Neoplasia https://ClinicalTrials.gov/show/NCT00889798 Completed iOMEDICO AG 2019-08-31
NCT03971318 A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBL https://ClinicalTrials.gov/show/NCT03971318 Recruiting Sun Yat-sen University 2022-05-05
NCT03971305 A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL https://ClinicalTrials.gov/show/NCT03971305 Recruiting Sun Yat-sen University 2022-05-05